This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
No criteria were used to ensure the validity of the primary studies.
Methods used to judge relevance and validity, and for extracting data
No methods were used to judge the relevance and the validity of the extracted data.
Number of primary studies included
Two primary studies provided the effectiveness data.
Methods of combining primary studies
The results of the individual primary studies were not combined.
Investigation of differences between primary studies
The authors did not investigate possible differences between the primary studies.
Results of the review
The prevalence of OSA stroke was 79% in the base-case scenario.
CPAP acceptance was 90% in the base-case scenario.
Measure of benefits used in the economic analysis
The measure of health benefit used was the quality-adjusted life-years (QALYs) gained. These were obtained from the model. All utilities were extracted from a published study. The basic method of valuation of health states was not reported in the current study, although further information can be obtained from an earlier study (Post et al. 2001 , see 'Other Publications of Related Interest' below for bibliographic details).
Direct costs
The health care costs included in the analysis were PSG, CPAP titration, and CPAP plus supplies for 3 months. The cost estimates were reported separately from other model parameters. The unit costs were reported but the quantities of resources used were not. All costs were derived from official published sources, but it seems that the costs were not appropriately adjusted for inflation and the price year was not reported. As the time horizon of the model was less than two years, discounting was not relevant. The incremental costs were estimated by modelling.
Synthesis of costs and benefits
The incremental analysis demonstrated that the screening strategy resulted in an incremental cost of $49,421 per additional QALY gained.
The two-way sensitivity analysis demonstrated that the PSG strategy remained under the threshold of $50,000 per QALY if the utility of patients with OSA on CPAP was 0.2 or higher in comparison with patients with OSA who were not on CPAP.
For a willingness-to-pay of $50,000 per QALY, the screening strategy remained cost-effective as long as the treatment of stroke patients resulted in an improvement of 50% or more in quality of life.
Equally, for a willingness-to-pay of $100,000 per QALY, the incremental utility due to treatment would have to be 25% or more.
Authors' conclusions
Screening is cost-effective as long as the treatment of stroke patients with obstructive sleep apnoea (OSA) by continuous positive airways pressure (CPAP) improves patient utilities by more than 0.2 for a willingness-to-pay of $50,000 per quality-adjusted life-year (QALY) and 0.1 for a willingness-to-pay of $100,000 per QALY. "A clinical trial assessing the effectiveness of CPAP in improving stroke outcome is warranted from a cost-effectiveness standpoint."
CRD COMMENTARY -Selection of comparators
The authors compared the PSG screening options against no screening and no alternative options were discussed. The strategy of no screening was included for comparative purposes.
Validity of estimate of measure of effectiveness
A systematic review of the literature does not appear to have been undertaken. Although this is common practice with models, in the current study it appears that studies have been selected from the literature according to convenience or the authors' preferences. Therefore, the effectiveness estimates derived may not be the best available. In addition, data from the available studies appear to have been used selectively. The study designs, other inclusion criteria for the review, and the sources searched to identify primary studies were not reported, and possible differences between the
